Regenxbio Inc reports results for the quarter ended December 31 - Earnings Summary

• Regenxbio Inc RGNX.OQ reported a quarterly adjusted loss of $1.01​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.43. The mean expectation of ten analysts for the quarter was for a loss of $1.15 per share. Wall Street expected results to range from $-1.34 to -46 cents per share.

• Revenue fell 4.5% to $21.21 million from a year ago; analysts expected $23.75 million.

• Regenxbio Inc's reported EPS for the quarter was a loss of $1.01​.

• The company reported a quarterly loss of $51.19 million.

• Regenxbio Inc shares had fallen by 13.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 2.3% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Regenxbio Inc is $28.50

This summary was machine generated from LSEG data March 13 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)